Why Insmed Shares Soared

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Insmed (NASDAQ: INSM  ) , a clinical-stage biotechnology company focused on inhaled therapies for diseases of the lung, jumped as much as 18% after a pair of brokerage firms boosted their price targets on the company.

So what: Just hours apart from one another, Canaccord Genuity boosted its price target on Insmed from $12 to $17 while Leerink Swann raised its target all the way to $22 from $13. The impetus behind both price target hikes was similar: an expected approval of Arikace, the company's inhaled first-line treatment for non-tuberculosis mycobacterial infections. These two price target bumps come one week after Lazard Capital Management raised its price target on Insmed to $21 and the covering analyst, Joshua Schimmer, projecting sales of $600 million annually by 2020.

Now what: While certainly a good day for existing shareholders, let's remember that analyst actions should be taken with a grain of salt as they rarely have any long-term bearing on a stocks' share price or your investing thesis. The reality here is that Insmed still doesn't have a drug approved by the Food and Drug Administration, it's burning cash, and it could be at least two more years before it gets Arikace in front of the European Medicines Agency for an approval decision. A U.S. decision will be yet another year or two beyond that. With a cash burn rate that I anticipate will be right around $50 million annually, it won't be long before Insmed needs cash again and reaches to potentially dilutive offerings to accomplish this. I'd strongly suggest keeping your distance.

Craving more input? Start by adding Insmed to your free and personalized watchlist so you can keep up on the latest news with the company.

While you can certainly make huge gains in biotechs like Insmed, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.


Read/Post Comments (3) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 22, 2013, at 2:02 PM, jad9000 wrote:

    Well, I guess if the analysts are targeting over $20 without this approval it will be $40 with the approval. And, of course, there are other indications that have a similar upside. And, there is also the other product sitting on the shelf due to patent issues - Iplex. We are a few years away from it coming back to market and it is well known to be far superior to Increlex, who loses patent protection then.

  • Report this Comment On May 23, 2013, at 7:51 AM, jklong59 wrote:

    I believe Phase 3 results are expected Mid 2013.

    I would think approval and sales would not be far behind since management is already making preparations.

  • Report this Comment On May 30, 2013, at 7:22 PM, boardwalk97 wrote:

    Are you commenting on the prospects for the company or pitching advertisement? Next time, bring the main course first to the stock research table vs an appetizer. MF usually brings a shovel to the dig!!

Add your comment.

DocumentId: 2447243, ~/Articles/ArticleHandler.aspx, 7/25/2014 12:24:51 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement